GlassScriptPhysician profile
Roger J Pede
NPI 1275538217
$2,327.30
in general payments reported to CMS, 2019-2025
20 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.85 · 2022: $103 · 2023: $73.24 · 2024: $506 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.83 | 2024-2025 | |
| Janssen Biotech, INC. | $490.74 | 2024-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $251.77 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $142.78 | 2024-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $131.52 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $128.14 | 2024-2025 | Iqirvo |
| Microvention, INC. | $88.20 | 2022-2023 | Stent, Headway Advanced Soft, V-Grip Detachment Controller |
| Pacira Pharmaceuticals Incorporated | $69.41 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.07 | 2024-2025 | Xifaxan |
| Cardiva Medical, INC. | $54.92 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Lilly USA, LLC | $50.85 | 2025 | Omvoh |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.64 | 2023-2024 | Lifevest |
| Ardelyx, INC. | $30.50 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $28.30 | 2024-2025 | |
| Blueprint Medicines Corporation | $24.56 | 2025 | Ayvakit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.89 | 2024 | Gi Genius |
| Madrigal Pharmaceuticals | $17.71 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $17.35 | 2024 | Dificid |
| Avanos Medical | $16.85 | 2022 | |
| Boston Scientific Corporation | $15.27 | 2025 | Orca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Pede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.